TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna’s mFlusiva mRNA flu vaccine is available in limited quantities this season after FDA approval in August, following pharmacy orders for flu vaccines. The manufacturer says it is offered at more than 13,000 locations; patients can use its vaccine finder or call pharmacies to check stock. Evidence comparing its clinical protection with enhanced flu vaccines remains limited.
Moderna’s mFlusiva, the first mRNA flu shot described in the report, is available in limited quantities this season after FDA approval in August came after major pharmacy chains had ordered their flu vaccine supplies. The company says the vaccine is available at more than 13,000 locations, but people looking for it may need to check Moderna’s vaccine finder or call pharmacies before visiting.
The vaccine is approved for adults ages 50 and older. A Moderna spokesperson told MedPage Today that the company planned a “limited launch in year one.” The spokesperson provided a link to the company’s vaccine finder, although the report does not give specific locations or confirm that every listed site has doses in stock.
Amesh Adalja, MD, of the Johns Hopkins Center for Health Security, said people who want mFlusiva may have to use the finder or call around. He told MedPage Today that pharmacies often order standard flu shots and may not distinguish between less commonly requested products when placing orders.
The report says all flu vaccines in the United States are now trivalent, covering three influenza strains. Other available options include standard-dose vaccines, the recombinant Flublok and cell-based Flucelvax, as well as enhanced-dose or adjuvanted vaccines for adults 65 and older. Availability and eligibility depend on the product.
Finding a Less Common Flu Vaccine
For patients who specifically want an mRNA flu vaccine, limited first-season supply means availability may depend on where they live and which products nearby pharmacies ordered. Checking before traveling can save time, and asking a pharmacist or clinician about other available flu vaccines can help people avoid delaying vaccination while searching for one brand.
The choice also involves weighing evidence and possible side effects. The report describes higher rates of injection-site pain, fatigue, headache and muscle pain in mFlusiva trial data than with standard-dose flu shots. Whether its immune-response findings translate into better clinical protection than enhanced vaccines is not yet established by head-to-head clinical-outcome studies, according to the experts cited.
Approval Came After Pharmacy Orders
The timing of the FDA decision is central to this season’s supply. Moderna’s vaccine was approved in August 2026, after national retail pharmacy chains had placed orders for the season’s flu shots. That left less time for the new product to be incorporated into routine ordering and stocking.
FDA approval covers adults ages 50 and older, but the agency used different approval pathways by age: traditional approval for those ages 50 to 64 and accelerated approval for people 65 and older. The latter group is subject to a planned postmarketing effectiveness study. The source report says a separate phase III study found a stronger immune response than Fluzone High-Dose among adults 65 and older, but it did not measure clinical outcomes such as prevention of illness.
Adalja said there are not good head-to-head studies comparing mFlusiva’s clinical outcomes with other enhanced vaccines. William Schaffner, MD, of Vanderbilt University, likewise cautioned that an immune response does not by itself establish better protection against flu.
“If someone wants to get mFlusiva, they’re going to have to use that website or call around.”
— Amesh Adalja, MD, Johns Hopkins Center for Health Security
Supply and Comparative Protection
The report does not identify which pharmacies or regions currently have mFlusiva in stock, how many doses are available, or whether the company’s finder reflects live inventory. A location listed by the manufacturer may not necessarily have doses available when a patient checks.
It also remains unclear whether mFlusiva offers better clinical protection than enhanced flu vaccines. The cited studies report immune-response findings, but the report says there are no good head-to-head clinical-outcome studies against enhanced products. The FDA has required a postmarketing effectiveness study for adults 65 and older; its timing and findings are not provided.
Check Local Stock Before You Go
People seeking mFlusiva can start with Moderna’s vaccine finder and contact a listed pharmacy to confirm availability, eligibility and appointment requirements. If the shot is unavailable, they can ask a pharmacist or healthcare professional about other flu vaccines offered locally rather than waiting indefinitely for a specific product.
The next evidence milestone is the planned postmarketing effectiveness study for adults 65 and older. The report does not give a completion date. In the meantime, Schaffner said flu activity had started early in many parts of the country and advised people who had not been vaccinated to get an available flu vaccine.
Key Questions
Where can I find mFlusiva?
Moderna has a vaccine finder for the shot, which the company says is available at more than 13,000 locations. Call a pharmacy before visiting to confirm it has doses in stock.
Who is eligible for Moderna’s mRNA flu vaccine?
The report says mFlusiva is approved for adults ages 50 and older. Ask a pharmacist or healthcare professional about eligibility and local availability.
Why is mFlusiva hard to find this season?
The FDA approved it in August, after major pharmacy chains had placed orders for the season’s flu vaccines. Moderna also described its first-year rollout as limited.
Has mFlusiva been shown to protect better than enhanced flu shots?
That has not been established by head-to-head clinical-outcome studies, according to the experts cited by MedPage Today. A phase III study found a stronger immune response than Fluzone High-Dose in adults 65 and older, but did not assess clinical outcomes.
Should I wait for mFlusiva if it is not available nearby?
Schaffner advised people who have not been vaccinated to get an available flu vaccine rather than wait for a specific product. A healthcare professional or pharmacist can discuss local options.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
